Ganymed Pharmaceuticals Overview

  • Founded
  • 2001
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 85
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $1.41B
Latest Deal Amount

Ganymed Pharmaceuticals General Information

Description

Developer of antibody therapeutics for the treatment of solid cancers. The company is building a pipeline of antibody therapeutics targeting solid cancers with medical need and large-market potential. It also focuses on developing ideal monoclonal antibodies that include cancer-selective targets for maximal high-precision anticancer potency as well as mitigates the threat of toxicity.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Other Commercial Services
Other Industries
Drug Discovery
Pharmaceuticals
Discovery Tools (Healthcare)
Acquirer
Primary Office
  • An der Goldgrube 12
  • 55131 Mainz
  • Germany
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ganymed Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 11-Nov-2016 $1.41B 00000 00.000 Completed Generating Revenue
6. Later Stage VC (Series E) 18-Nov-2013 000.00 00000 Completed Generating Revenue
5. Later Stage VC (Series D) 18-Nov-2008 000.00 000.00 Completed Generating Revenue
4. Merger/Acquisition 21-Aug-2008 000.00 Completed Generating Revenue
3. Later Stage VC (Series C) 18-Apr-2007 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 06-Jul-2005 $17.4M $25.5M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 01-Jun-2002 $8.14M $8.14M Completed Startup
To view Ganymed Pharmaceuticals’s complete valuation and funding history, request access »

Ganymed Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of antibody therapeutics for the treatment of solid cancers. The company is building a pipeline of antibody th
Other Commercial Services
Mainz, Germany
85 As of 2016
00000
0.000 0000-00-00
000000&0 00000

0000000

exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repr
000000000000000
Cambridge, MA
000 As of 0000
000.00
000000000 000.00

00000

reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaec
0000000000000
Thousand Oaks, CA
00000 As of 0000
00.000
000000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ganymed Pharmaceuticals Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sarepta Therapeutics Formerly VC-backed Cambridge, MA 000 000.00 000000000 000.00
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
0000000 0000000000 Corporation Emeryville, CA 000 00000 000000000 00000
000000000 00000000 Formerly VC-backed Rockville, MD 00 000.00 000000&0 000.00
000000000 Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
You’re viewing 5 of 8 competitors. Get the full list »

Ganymed Pharmaceuticals Executive Team (7)

Name Title Board Seat Contact Info
Ozlem Tureci MD Co-Founder, Chief Executive Officer & Chief Medical Officer
Dirk Sebastian Co-Founder, Chief Operating Officer & Chief Financial Officer
Ugur Sahin Ph.D Advisor & Co-Founder
Christopher Huber MD Co-Founder, Vice Chairman and Deputy Chairman Supervisory Board
You’re viewing 4 of 7 executive team members. Get the full list »

Ganymed Pharmaceuticals Board Members (12)

Name Representing Role Since
Christopher Huber MD Self Co-Founder, Vice Chairman and Deputy Chairman Supervisory Board 000 0000
You’re viewing 1 of 12 board members. Get the full list »

Ganymed Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ganymed Pharmaceuticals Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ATS Beteiligungsverwaltung Family Office Majority 000 0000 000000 0
Daniel Gutenberg Angel (individual) Minority 000 0000 000000 0
First Capital Partners (Germany) Other Minority 000 0000 000000 0
Future Capital Venture Capital Minority 000 0000 000000 0
Ingro Finanz Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »